Serum tumor markers in chronic kidney disease: as clinical tool in diagnosis, treatment and prognosis of cancers

Size: px
Start display at page:

Download "Serum tumor markers in chronic kidney disease: as clinical tool in diagnosis, treatment and prognosis of cancers"

Transcription

1 Renal Failure ISSN: X (Print) (Online) Journal homepage: Serum tumor markers in chronic kidney disease: as clinical tool in diagnosis, treatment and prognosis of cancers Fateme Shamekhi Amiri To cite this article: Fateme Shamekhi Amiri (2016) Serum tumor markers in chronic kidney disease: as clinical tool in diagnosis, treatment and prognosis of cancers, Renal Failure, 38:4, , DOI: / X To link to this article: Published online: 24 Feb Submit your article to this journal Article views: 1083 View related articles View Crossmark data Citing articles: 1 View citing articles Full Terms & Conditions of access and use can be found at Download by: [ ] Date: 01 January 2018, At: 10:53

2 Renal Failure, 2016 VOL. 38, NO. 4, STATE OF THE ART REVIEW Serum tumor markers in chronic kidney disease: as clinical tool in diagnosis, treatment and prognosis of cancers Fateme Shamekhi Amiri Division of Nephrology, Imam Khomeini Hospital, Faculty of Medicine (Poursina), Tehran University of Medical Sciences, Tehran, Iran ABSTRACT Cancer is singled out as the biggest cause of death in the world, predicted to reach 13.1 million cancer-related deaths by the year Although there are no specific tumor markers used in cancer screening, some markers can be used to assist in making a diagnosis and determining a prognosis. They can be used to follow in cases where the diagnosis is cancer through monitoring of the disease recurrence and/or evaluating the response to therapy. These markers are not specific as the number increases in multiple cases of cancer. Some markers are positive in a single type of cancer; others are detectable in more than one type. An ideal tumor marker should be highly sensitive, specific, and reliable with high prognostic value. Other characteristics of an ideal tumor marker are organ specificity and correlation of it with tumor stages. However, none of the tumor markers reported to date has all these characteristics. Influence of different stages of chronic kidney function on serum tumor markers is variable. Furthermore, hemodialysis, peritoneal dialysis, and kidney transplantation affect on tumor markers differently. Sometimes, no study has been found in the literature review. Combined serum tumor markers may also be valuable. This literature review points the role of serum tumor markers in screening, diagnosis, and follow-up of cancer patients in chronic kidney disease patients and renal allograft recipients. In addition, impact of chronic kidney disease and kidney transplantation on different serum tumor markers is briefly explored. Introduction Cancer is one of the diseases which is found to be a major leading cause of death in worldwide due to the late diagnosis of the disease. Hence, early diagnosis of cancer plays a very important role in the management and the cure of the disease. Also, it has been known that besides the increased risk of cardiovascular mortality, chronic kidney disease is an important risk factor for cancer mortality. Patients with chronic kidney disease have a higher mortality risk of liver, kidney, and urinary tract cancers. 1 Therefore, early diagnosis of cancers with the help of serum tumor markers seems to be necessary. This paper is based on a systematic review of large literature and has been conducted through literature searches using medical subject headings that combined with terms for chronic kidney disease or dialysis or kidney transplantation. This also includes the method supplemented with author s working knowledge and reference lists of review article and textbooks, and with references in articles that author found relevant. Definition of serum tumor markers ARTICLE HISTORY Received 9 October 2015 Revised 19 January 2016 Accepted 23 January 2016 Published online 23 February 2016 KEYWORDS Cancers; chronic kidney disease; dialysis; kidney transplantation; tumor markers Neoplastic cells secrete proteins that can mark their activities. The first tumor marker was discovered in However, now more than 100 different tumor makers are available. The serum tumor markers are proteins or glycoproteins which depending on their type are secreted by tumoral and normal cells. Tumor marker concentrations in healthy individuals is low or zero, and its increasing concentrations suggest the incidence of related tumor (Figure 1). 2 Tumor markers are widely used in monitoring cancer patients and for screening of certain tumors. It has recently been shown that concentrations of some tumor markers are higher in patients with chronic kidney disease (CKD) than in healthy subjects (Table 1). Ideal tumor marker should be positive in patients only if malignancy is present or in progress, correlated with stage and response to treatment, repeatedly detectable, and easily measured. Unfortunately, such an ideal marker does not exist as yet. 3 Common tumor markers are described in the following sections. CONTACT Dr Fateme Shamekhi Amiri fa.shamekhi@gmail.com Division of Nephrology, Imam Khomeini Hospital, Faculty of Medicine (Poursina), Tehran University of Medical Sciences, Tehran, Iran ß 2016 Taylor & Francis

3 RENAL FAILURE 531 Figure 1. Schematic presentation of various cancers that are associated with elevated tumor markers. Underlined cancers indicate primary tumors and others imply additional associated malignancies. Note: AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; HCG, human chorionic gonadotropin; PSA, prostate-specific antigen. Prostate-specific antigen in chronic kidney disease The prostate-specific antigen (PSA) remains the best and most widely used tumor marker for prostate in clinical practice. PSA is a serine protease, which is produced by prostatic alveolar and ductal epithelial cells and it is a glycoprotein with a molecular weight of 33 kda. PSA is commonly used in the diagnosis and follow-up of prostate disease especially prostate cancer. PSA was introduced into clinical practice in 1986, the early diagnosis and management of prostate cancer has been revolutionized. The PSA test is the most effective test that is currently available for the early detection, diagnosis, and follow-up of prostate cancer in kidney disease patients. 4 Prostate-specific antigen occurs in several molecular forms in the blood, with two predominant forms: free, non-complexed PSA (fpsa) with a molecular mass of 28 kda and complexed PSA (cpsa), a stable 90 kda complex with alpha-1 antichymotrypsin. PSA also occurs in complex with alpha-1 antitrypsin and alpha-2 macroglobulin but at much lower levels and of certain clinical value. The sum of fpsa and cpsa roughly corresponds to the conventional immunodetected total PSA (tpsa). Increased release of tpsa in the blood is caused by prostate cancer but also by other prostate disorders, such as benign enlargement and prostatitis. However, fpsa as a percentage of tpsa (percent fpsa) is lower in men with prostate cancer than in men with benign disorders. Half-life for fpsa in serum is short (4-34 h).

4 532 F. S. AMIRI ET AL. Table 1. Changes of serum tumor markers in NDD-CKD, hemodialysis, peritoneal dialysis, and renal transplant recipients. Tumor marker Primary cancer Predialysis Hemodialysis (HD) Peritoneal dialysis Kidney transplantation Reliability PSA Prostate cancer "fpsa,"%fpsa "fpsa,"%fpsa "fpsa,"% fpsa #fpsa,$tpsa tpsa in HD fpsa and fpsa/tpsa ratio with low flux dialyzer mm CA 15-3 Breast cancer ",$ ",$ ",$ ",$ No reliable for screening CA Breast cancer CA 19-9 Pancreatic, ",$ ",$ ",$ ",$ Interpret with caution in HD biliary tract cancers CA 125 Ovarian cancer ",$ ",$ " $ Interpret with caution in HD CA 72.4 Ovarian cancer Afamin Ovarian cancer No study available # in acute rejection HE4 Ovarian cancer " " " AFP Hepatoma $ $ $ $ Reliable in HD CEA " " b2m LPD, MPD " " " # HCG (b-subunit) Germ cell tumors " " " " Reliable in HD Chromogranin A NET " " NA " Note: AFP: alpha-fetoprotein; b2-m: beta-2 microglobulin; CEA: carcinoembryonic antigen; fpsa: free prostate-specific antigen; fpsa: free prostate specific antigen; HCG: human chorionic gonadotropin; HE4: human epididymis protein 4; LPD: lymphoproliferative disorders; mm: membrane; MPD: myeloproliferative disorders; NA: not applicable; NET: neuroendocrine tumors; NDD-CKD; non-dialysis dependent - chronic kidney disease; PSA: prostate-specific antigen; tpsa: total prostate-specific antigen. Figure 2. Different studies of prostate specific antigen (tumor marker) in chronic kidney disease. Note: AFP: alpha-fetoprotein; CAPD: continuous ambulatory peritoneal dialysis; CKD: chronic kidney disease; %fpsa: percent free prostate-specific antigen; HCG: human chorionic gonadotropin; HD: hemodialysis; PSA: prostate-specific antigen; PSAD: prostate-specific antigen density. This, combined with its low molecular mass, suggests elimination by glomerular filtration. In contrast, cpsa has slow elimination kinetics and 3-fold larger molecular mass, which prevents glomerular filtration; these observations suggest other routes of elimination, most likely by liver metabolism. Therefore, diminished renal elimination of fpsa may affect percent fpsa and its accuracy as a diagnostic tool for prostate cancer. In a study by Bruun et al., men with chronic kidney disease without prostate cancer and also 5264 men with no diagnosis of prostate cancer during 8 years follow-up were considered. With adjustment for age, median fpsa levels and percent fpsa were significantly higher in patients with renal dysfunction. The percent fpsa is importantly influenced by moderately impaired renal function in men with chronic kidney disease. For such men, use of the current clinical decision limits for percent fpsa could cause some men with prostate cancer to be misdiagnosed as having benign disease, and therefore fpsa should not be used to diagnose prostate cancer in these patients. Impaired renal function is thus an important factor to consider in the evaluation of percent fpsa for detection of prostate cancer. Prostate-specific antigen in chronic dialysis Both hemodialysis and peritoneal dialysis are believed to influence the PSA-based results and several studies have established these findings (Figure 2) Renal dysfunction may alter the relative proportions of the two PSA forms by decreasing the elimination of fpsa, thereby increasing percent fpsa. This has been confirmed by findings in men on hemodialysis and peritoneal dialysis treatment who had significantly higher percent fpsa. This raises the possibility that renal dysfunction may compromise the diagnostic accuracy of percent fpsa and suggests that a high percent fpsa could not be considered as a sign of benign prostatic disease in men with strongly reduced glomerular filtration rate (GFR) requiring chronic dialysis. 5 Prostate-specific antigen is a tumor marker that is used as a screening test, usually in combination with

5 RENAL FAILURE 533 digital rectal and/or ultrasound-guided examination. Evaluating tumor markers in dialysis patients can be difficult but total PSA is probably valid in patients with end-stage renal disease because total PSA is not cleared by dialysis membranes. Free PSA and free/total PSA ratios are reliable only with low-flux membranes. Free PSA in dialysis patients are less useful because free PSA tends to be elevated in association with hemoconcentration and its clearance is affected by high-flux dialysis membranes. Normal % free PSA do not apply to dialysis patients. 14,15 Prostate-specific antigen in kidney transplantation Cancer is the second to cardiovascular disease as one of the major causes of morbidity and mortality in renal transplant recipients. Cancers can recur, occur de novo, and be transmitted from donor organ in post-transplantation period. Renal transplant recipients (RTR) are at high risk for de novo cancers, especially skin cancer and post-transplant lymphoproliferative disorder (PTLD) with an incidence 4- to 20-fold higher than that in the general population. Genito-urinary (GU) malignancies have been reported to be the second most common malignancies in the RTR population in the United States. Prostatic cancer in renal transplant recipients is two- to five-fold higher than that in the general population. Kleinclauss et al. 16 in a retrospective, multi-centre study examined 62 patients in renal transplant recipients. This study highlights particular characteristics of prostate cancer in the RTR population. First, prostate cancer appears sooner in RTR than in the general population. Second, they observed a high rate of advanced or metastatic disease and third, the stage of the disease seems to be related with the immunosuppressive therapy (calcineurin inhibitors and azathioprine) usage. Hence, a systematic screening of prostate cancer is required in renal transplant recipients by an annual serum PSA level and direct rectal examination In a study by Mahdavi et al., patients who were on peritoneal dialysis or hemodialysis underwent kidney transplantation. Free PSA levels were significantly decreased after kidney transplantation but total PSA remained unchanged. This was observed in post-transplant patients irrespective of whether they had delayed graft function, slow graft function, or immediate graft function during the observed period. Therefore, total PSA can be used as a marker for prostate cancer screening after kidney transplantation. Other interesting points about prostatic-specific antigen contain situations that may change PSA values like inflammations, traumatic interventions, and immunosuppression. Chamie et al., 19 in their study concluded that only immunosuppression with sirolimus independently impacted post-transplant PSA. Their data strongly suggest that sirolimus is associated with a significant decreased level of PSA in kidney transplantation. CA 15-3 and CA in chronic kidney disease CA 15-3 (also known as MUC1 or EMA) is the serum marker most widely used in breast cancer. Like CA 125, MUC1/CA 15-3 is a member of the mucin family and is a membrane-associated O-glycoprotein with a large extracellular domain. CA 15-3 is expressed on the apical membrane of almost all glandular epithelia, and in normal kidney it is localized in the distal convoluted tubules and in the collecting ducts. CA 15-3 has a significant role in cell adhesion and cellular polarity and through its intracellular domain is implicated in signal transduction, interacting with the epidermal growth factor (EGF) receptor, and activating the mitogenactivated protein (MAP) kinase pathway. 20 CA 15-3 is structurally a glycoprotein that is principally detected by immunoabsorption and may be elevated in patients with breast, ovarian, prostate, and lung cancer and is also reported to be increased in hepatitis conditions, benign breast or ovarian disease, endometriosis and pelvic inflammatory disease. 21 CA 15-3 and CA are, substantially, the same molecule but measures of different epitopes of the same protein antigen product of the MUC1 gene. Normal serum levels of CA 15-3 and CA are less than 31 and 38 units/ml, respectively. Serum levels of CA 15-3 and CA are not useful for breast cancer diagnosis, but their use is recommended in metastatic breast cancer treatment, since they reflect the course of disease in 75 to 90% of patients undergoing therapy. However, the routine use of serial tumor measurement of these markers in the post-treatment surveillance of women with breast cancer is controversial, particularly in patients with chronic kidney disease and renal replacement therapy. 3 CA 15-3 in chronic dialysis and kidney transplantation In a study by Tzitzikos et al., patients on intermittent hemodialysis and with clinical-free neoplastic disease to determine the reliability of the serum markers, CA 15-3, CA 19-9, CA 125, alpha-fetoprotein and CEA were selected. CA 15-3 levels were twice normal in four (13%) patients. More than half (7/13) of anti-hcv positive and all of Australian antigen positive patients had abnormal serum levels of CA 15-3 and CA 125 after hemodialysis treatment. However, the elevated levels of other markers including CA 15-3 and CA 125 are not

6 534 F. S. AMIRI ET AL. specific for neoplasms and are related to active hepatitis C. Another study by Estakhri et al., patients were selected for the study to investigate differences between serum levels of tumor markers CA 15-3, AFP, CA 19-9 and CEA in patients with impaired renal function. A significant correlation was observed between serum levels of AFP and CA 15-3 and also a tendency between creatinine clearance and CEA. Creatinine clearance significantly correlated with AFP and CA 15-3, but not CA Therefore, for the diagnosis and follow-up of cancer patients with kidney failure by AFP, CA 15-3 should be taken with the necessary precautions and if possible, another more reliable method that is not affected by renal failure can also be used. Moreover, in a study by Xiaofang et al., non-dialysis patients with CKD and 37 uremic patients on maintenance hemodialysis were enrolled. The serum concentrations of CA 19-9, CA 125 (male), cytokeratin fragment 21-1 (CYFRA 21-1), neuronspecific enolase (NSE), and squamous cell carcinoma (SCC-Ag) correlated negatively with creatinine clearance, while there were no significant differences in the concentrations of CA 125 (female), AFP, CA 15-3, and CA The serum levels of CA 19-9, CA 125, AFP, CA 15-3, CA 72.4, CYFRA 21-1, NSE and SCC-Ag showed no differences between hemodialysis patients and nondialysis controls. The increase in the serum levels of CA 19-9, CA 125 (in males), CYFRA 21-1, NSE and SCC-Ag in patients with CKD affects the specificity of these markers in the diagnosis of cancer. Hemodialysis does not affect the serum levels of CA 19-9, CA 125, AFP, CA 15-3, CA 72.4, CYFRA 21-1, NSE, and SCC-Ag. CA 19-9 and CA 50 in chronic kidney disease Carbohydrate antigen 19-9 (CA 19-9) is a 36-kDa glycolipid detected in low levels in serum of healthy individuals. It is used as a marker for biliopancreatic malignancies and levels of it can be increased with other types of cancer, including gastric, colorectal, hepatic, ovarian, and transitional cell carcinoma. CA 19-9 levels can also increase in cases of biliary obstruction of nonmalignant origin, as well as in benign hepatobiliary conditions, in which it correlates with serum bilirubin concentration. Increased serum CA 19-9 levels have also been reported with other non-malignant conditions. Levels of greater than the upper limit of normal are found in % of healthy individuals. 24 Appreciable concentration of CA 19-9 is also present in mucin rich saliva, seminal fluid, gastric juice, amniotic fluid, urine, ovarian cyst fluid, pancreatic, gall bladder, and duodenal secretions. In 99.6% of healthy adults, serum CA 19-9 levels are lower than 37 unit/ml. Value less than 100 U/mL is considered as grey zone values in which malignant and benign diseases may overlap. Malignant tumors in values above 100,000 U/L may be observed. CA 19-9 is neither tumor specific nor organ specific. However, the diagnostic sensitivity (85%) and specificity (95%) of CA 19-9 are highest for the adenocarcinoma of pancreas. 25 Moreover, the diagnostic performance of the biomarker is closely related to tumor size. Serial monitoring of CA 19-9 levels is useful for follow-up of patients after surgery and those who are receiving chemotherapy for advanced disease. In different studies, such as Zeferos et al. s, 26 tumor markers of AFP, CEA, CA 19-9, CA 125, and CA 15-3 were studied in 50 healthy volunteers (group A), in 23 patients on chronic hemodialysis (group B), and in 30 successfully transplanted individuals (group C). The levels of CA 19-9 and CA 125 did not differ significantly among the three groups. CA 19-9 and CA 125 can be considered as reliable tumor markers in patients undergoing hemodialysis or kidney transplantation. In a study by Xiaofang et al., 23 the increase in the serum levels of CA 19-9, CA 125 (in males), CYFRA 21-1, NSE and SCC-Ag in patients with CKD affects the specificity of these markers in the diagnosis of cancer. Hemodialysis does not affect the serum levels of CA Oberbauer et al., 27 the specificity and the sensitivity of tumor markers of AFP, CA 19-9, CEA, CA 125, CA 15-3, PSA, and calcitonin in 575 renal allograft recipients were evaluated. Impaired liver function was associated with significantly elevated AFP, CA 19-9, CA 125, and CA 15-3 levels. Finally, routine screening of the transplant population with serum tumor markers was not useful because of the low sensitivity and specificity of these tests. In addition, studies by Estakhri et al. 2 and Tzitzikos et al. 22 showed that CA 19-9 with presence of increased levels is not specific for neoplasms after hemodialysis treatment. Wood et al. 28 concluded that single isolated determinations of CA 125 and CA 19-9 are not reliable indicators of malignancy in renal transplant patients. Therefore, CA 19-9 and CA 50 (similar in structure to CA 19-9) should be interpreted with caution, often elevated in dialysis patients but has good specify and of some clinical value, often moderately elevated with peritoneal, pleural, or pericardial fluids. 15,21,25 CA 125, HE4, and CA 72.4 in chronic kidney disease CA 125 (cancer antigen 125 or carbohydrate antigen 125), a tumor-associated glycoprotein of more than 200 KD.CA 125 (also known as MUC16) is a high molecular weight glycoprotein used mainly as a diagnostic biomarker for ovarian cancer. Elevated levels of this protein have also been found in tumors of the pancreas, lung, breast, and bladder, as well as in

7 RENAL FAILURE 535 different benign diseases. 3,20,25 It is a component of the ocular surface, respiratory tract, and female reproductive tract epithelia. Normal values range from 0 to 35 unit/ ml. CA 125 levels may be higher in premenopausal than postmenopausal women and half-life of it is approximately, 5-7 days. 29 In patients with elevated CA 125 levels, changes in biomarker levels have tracked tumor burden with greater than 90% accuracy. Persistent elevation of CA 125 following chemotherapy has correlated with residual ovarian cancer in 490% of cases, leading to approval of CA 125 by the United States Food and Drug Administration (FDA) for detection of disease that has survived primary chemotherapy. Monitoring CA 125 levels in patients with a complete clinical response can detect recurrence of cancer in up to 70% of patients, with an average lead time of 3 to 4.8 months. The clinical value of early detection of disease recurrence has been questioned, that is based on a single study with significant limitations, but it does provide time for patients to receive multiple conventional drugs and to participate in clinical trials with novel agents. Human epididymis protein 4, or HE4, was discovered by Kirchhoff and associates in 1991 and belongs to the four disulfide core family of proteins, which typically function as proteinase inhibitors. HE4 promotes migration and adhesion of ovarian cancer cells and in in vitro studies, HE4 knockdown resulted in tumor growth inhibition. HE4 may have an additional role in maintaining the innate immunity of the respiratory tract and the oral cavity. Various factors aside from malignancy may influence serum HE4 levels and should be carefully considered in interpreting values of HE4. Unlike CA 125 levels, which decrease with age, HE4 levels increase significantly with age. HE4 levels are also affected by pregnancy: pregnant women have significantly lowered levels of HE4 in comparison with agematched non-pregnant premenopausal women. Older women, women with a later menarche, and smokers had also significantly higher levels of HE4 compared with appropriate controls. Levels of CA 125, Carcino-embryonic antigen (CEA), squamous cell carcinoma antigen (SCC), Neuron specific enolase (NSE) can be falsely elevated and have to be interpreted with caution. Levels of CA 125 are also altered in patients on continuous ambulatory peritoneal dialysis (CAPD) and have been noted to rise in peritonitis and immediately after implantation of the catheter. 30 In a study by Engin et al., 21 levels of CA 125 were higher in CAPD patients than in the control and other groups. Aside from these factors, menstrual cycle, endometriosis, estrogen and progestin contraceptive usage do not alter serum levels of HE4. HE4 has emerged as a valuable biomarker for both ovarian and endometrial cancer. HE4 has been evaluated for distinguishing malignant from benign pelvic masses, prognostication, monitoring, and screening. Elevation of HE4 can occur in renal failure and in lung cancer. 31 HE4 is a superior biomarker for distinguishing benign from malignant gynecological disease. A combination of CA 125 and HE4 was found to be a better predictor of malignancy than either marker alone. This combination was also found to have diagnostic relevance in the setting where there is a need to distinguish endometrial cancer from benign uterine disease, with a sensitivity of 60.4% and a specificity of 100%. Using a combination of HE4 and CA 125 increased overall sensitivity to 76%. A combination of CA 125 and HE4 may offer better lead times and sensitivity for the detection of recurrent ovarian cancer. 32 HE4 levels may also aid in monitoring response to therapy. A combination of sophisticated imaging techniques combined with HE4 marker levels may aid in following patients with peritoneal carcinomatosis. 33 Cancer antigen 72.4 (CA72.4), a glycoprotein, which increases in gastric, colon, breast, and ovarian adenocarcinomas, may be employed alone or in combination with CA 125 and HE4. CA 72.4 is less sensitive than CA 125 for epithelial ovarian carcinoma (EOC), but it is not influenced by pregnancy or the phase of menstrual cycle. 34 Yontem, 35 in a research, investigated 24 patients with CKD on hemodialysis without malignancy and 24 people as the control group. In both groups, blood sample for serum tumor markers of CEA, CA 125, CA 15-3, and AFP were analyzed. There were no significant difference between the results of AFP and CA 125 of both groups. Therefore, serum tumor markers may increase in the patients with chronic kidney disease due to damaged renal clearance and elimination without malignancy. There were no significant differences in the concentrations of CA 125 (female), AFP, CA 15-3, CA The serum levels of CA 19-9, CA 125, AFP, CA 15-3, CA 72.4, CYFRA 21-1, NSE, and SCC-Ag showed no differences between hemodialysis patients and non-dialysis controls. Hemodialysis does not affect the serum levels of CA 19-9, CA 125, AFP, CA 15-3, CA 72.4, CYFRA 21-1, NSE, and SCC-Ag. 2,22,23,26,27 CA 125 serum levels are not influenced by kidney transplantation. Afamin and apoa-iv are expressed predominantly in liver and small intestine, respectively. It will also be interesting to look at possible accumulations of both proteins in the ascitic fluid of the tumor and other properties of these proteins, such as anti-oxidative properties. Afamin accounts as an adjunct marker to CA 125 in ovarian cancer. 36 So far, no study has performed about Afamin in chronic kidney disease. The human glycoprotein of Afamin is primarily of hepatic origin and abundant concentrations are found in plasma,

8 536 F. S. AMIRI ET AL. cerebrospinal fluid, ovarian follicular, and seminal fluid. Afamin is strongly associated with metabolic syndrome. 37 In a study by Freue et al., 38 plasma concentration of Afamin for diagnostic purposes in patients with biopsy-confirmed acute rejection (BCAR) were measured and results revealed decreased levels of Afamin in blood. This study provides evidence that protein concentrations in plasma may provide a relevant measure for the occurrence of BCAR and offers a potential tool for immunologic monitoring. Alpha-fetoprotein Alpha-fetoprotein (AFP), a very popular and extensively studied carcinoembryonic glycoprotein/oncofetal antigen, is a major fetal serum globulin with a molecular weight of approximately 65,000. The single chain of glycoprotein has carbohydrate content of 3% and amino-acid sequence similar to albumin. It is expressed during malignancy or during intra-uterine or early postnatal life. It is found in fetal liver, yolk sac, and the gastrointestinal tract. Consequently, AFP correspondingly increased in about 80% of patients with hepatoma, 60% patients with non-seminomatous germ cell cancers, and occasionally in patients with other cancers. Although, abundant in fetal blood, its concentration in normal adults is below 15 ng/ml. The appearance of excess amount of serum alpha fetoprotein beyond 500 ng/ml indicates underlaying malignancy except in the cases of pregnancies. 21,25 Serum AFP measurement is a valuable clinical aid in diagnosis, prognosis, and monitoring of primary hepatocellular carcinoma, hepatoblastoma, non-seminomatous testicular germ cell tumors, the embryonal carcinoma, teratoma, choriocarcinoma and yolk sac carcinoma, germ cell tumors of ovary, and extra-gonadal germ cell tumors. Approximately, 60-90% patients with primary hepatocellular carcinoma have serum AFP concentrations more than 500 ng/ml. Very significant elevation of serum AFP is documented rarely in malignancies of gastrointestinal tract, pancreas, lung, kidney, breast, and etc. Regenerated hepatic tissue following liver damage due to viral hepatitis, chemically induced necrosis, and liver surgery have also associated with moderately raised AFP levels. An increase in serum AFP concentration below 400 ng/ml was also reported in 10-15% cases of acute and chronic hepatitis, liver cirrhosis, and secondary hepatic malignancies. Serial AFP estimations help in distinguishing non-malignant and malignant conditions, as steady and progressive rise of AFP is observed in malignancies, whereas non-malignant conditions show fluctuations and transient moderately elevated concentrations. Measurement of serum AFP has been helpful as laboratory aid in diagnosis and prognosis of AFP secreting malignancies, it has also been useful in monitoring efficacy of chemotherapy, surgery, and radiotherapy in primary hepatocellular carcinoma, hepatoblastoma, non-seminomatous testicular, and other germ cell tumors. AFP should not be used for tumors other than hepatocellular carcinoma, hepatoblastoma, and NSGCT. In particular, AFP should not be used for metastasis to liver. Half life of AFP in serum is approximately 5 days. 29 In many studies, the serum levels of AFP have been shown to be unaltered in patients with CRF, ESRD, hemodialysis, peritoneal dialysis, and renal transplantation. 2,3,15,21,35 Beta2-Microglobulin In 1968, Berggard and Bearn isolated b2-microglobulin (b2m). It is a 100 amino-acid single polypeptide chain, with a globular structure maintained by a disulfide bond linking two cysteines in position 25 and 80, respectively. It has a molecular weight of 11,815 Da and a stokes radius of 16 angstrom. It is found at the surface of human cells expressing major histocompatibility (MHC) class I. 39 b2-m is a low molecular weight protein and is part of the human leukocyte antigen (HLA) molecule, representing invariant light chain. It exists in the membrane of almost all nucleated cells, and is detectable in all body fluids as a shedding product of the cell membrane. The levels of serum and urine b2-m are also found to be increased in patients with some tumors, including solid tumors and leukemia. Thus, the levels of serum b2-m have become one of the most important prognostic factors and predictors of survival in patients with some tumors. 40 The role of b2-m has been demonstrated in several solid cancers and leukemia; however, the mechanism of b2-m action is poorly understood. Although increased b2-m serum levels in patients with breast cancer have been previously reported, the clinical value of b2-m as a prognostic factor and predictor of survival and also its mechanism in patients with breast cancer need further study, since breast cancer has different molecular subtypes and patients with the same clinical stages and pathological types of breast cancer that treated with same scheme, have different therapeutic and prognostic effects. In addition to the roles of b2-m in immunity, several other b2-m functions with clinical relevance have been elucidated, including the regulation of survival, proliferation, metastasis, and even apoptosis of cancer cells. Elevated b2-m has been observed in patients with renal failure and autoimmune and infectious diseases. Furthermore, increased synthesis and release of b 2 -M occurs in several malignant diseases including multiple

9 RENAL FAILURE 537 myeloma, lymphoma, and solid tumors as indicated by elevated serum or urine b2-m concentrations. Also, level of b2-m is one of the most important independent prognostic factors and survival predictors for some cancers. 41 In diseases with an activated immune system and in hematologic cancers (leukemia, lymphoma, and myeloma), the b2-m synthesis in serum is enhanced. b2-m is filtered by glomeruli and catabolized in the tubuli. Serum b2-m concentrations are correlated inversely to residual renal function. Although serum levels of b2-m in healthy persons range between 1.5 and 3 mg/l, concentrations of 20 to 50 mg/l are found in patients with ESRD. b2-m concentrations increase with chronic kidney disease stage and are highest in hemodialysis (HD) patients. One study showed that renal transplantation, which reduced b2-m serum levels, inhibited the development of dialysis-related amyloidosis and alleviated its symptoms. b2-m is considered as a marker for dialysis adequacy of molecules in the middle molecular weight range. b2-m was found to promote the growth of human renal cell carcinoma through activation of the protein kinase A, cyclic adenosine monophosphate (AMP) - responsive element-binding protein and vascular endothelial growth factor axis. Overexpression of b2-m in human prostate cancer cell lines leads to inhibition of tumor growth in vivo and using the b2-m antibody to interrupt b2-m signaling in human prostate cancer cell lines inhibits cancer cell growth and induces cell apoptosis. 42 Another study speculated that the upregulation of b2-m expression may contribute to the oncogenesis of human oral mucosa, tumor invasion, and metastasis. 43 Other interesting point about b2-m is that expression ratio of Map7/b2-M may serve as a valuable prognostic marker in patients with Stage II colon cancer, and potentially guide therapeutic decision making. 44 As b2-m is cleared by the kidneys, b2-m levels also reflect renal function. In addition, as b2-m may also be part of the acute-phase response, non-specific elevation in b2-m may occur as a result of other immune stimulation, such as acute viral infection. b2-m is expressed in human prostate cancer cell lines and tissues. Serum b2-m levels are elevated in patients with metastatic, androgen-independent prostate cancer. b2- M is a secreted protein expressed in prostate cancer, which is more specific for androgen stimulation. 45 In a study performed by Rodriguez et al., patients to investigate the prognostic significance of serum b2-m levels among patients with chronic myelogenous leukemia (CML) were enrolled. Serum b2-m levels are an important, and probably independent, prognostic factor for patients with CML in early chronic phase that are treated with interferon (IFN)-based therapy. b2-m has been advocated as a better predictor of glomerular filtration rate (GFR), but its serum concentrations can increase as an acute-phase reactant in disorders, such as lupus nephritis. It has been shown that b2-m may be a more sensitive marker of renal function than serum creatinine, but it is overtly affected by non-renal factors. b2-m may be useful as a renal marker in specific situations, such as renal transplant monitoring. 47 However, the mean predialysis b2-m concentration over time was predictive of all-cause mortality, independent of the dialyzer b2-m clearance and the residual renal function. Higher b2-m levels correlate with various cardiovascular risk factors and inflammation markers, such as C-reactive protein (CRP), interleukin-6 (IL-6) and tissue necrosis factor (TNF-a) and are associated independently with cardiovascular mortality and cardiovascular events. However, when the oxidative burst of leukocytes was investigated, b2-m did not show proinflammatory properties and therefore may not by itself be a causative factor of vascular damage. The serum b2-m level is also a new predictor of diabetes-related mortality in diabetic patients irrespective of renal function and is associated positively with insulin resistance. Successful kidney transplantation results in a substantial decrease in b2-m levels, but a delayed decrease or subsequently increasing levels after transplantation may serve as a marker of acute rejection or inflammation, including cytomegalovirus infection and post-transplant lymphoproliferative disease. However, the relevance of posttransplant b2-m levels for long-term prognosis is unknown. A retrospective cohort study showed that serum b2-m at discharge is a potent predictor of longterm mortality and graft loss in kidney transplant recipients, providing information on allograft function beyond serum creatinine. 48 Elevated b2-m levels are observed in chronic renal failure, lymphoproliferative disorders, inflammations, infections and other conditions with high cell turnover. A relationship has been noted between tumor burden and b2-m. Concerning its use in oncology, b2-m levels correlate with the disease stage and poorer prognosis in patients with multiple myeloma and chronic lymphocytic leukemia. It is also the most important predictor of treatment-free survival and overall survival of patients that affected by lymphocytic leukemia and in most cases of lymphatic neoplasia. 49 Based on the findings of a study by Raikou and Kyriaki, 50 they investigated that elevated serum concentrations of b2-m predispose to an up-regulation of the inflammatory procedure, which is associated with the increased glucose serum concentrations in dialysis patients. On the other hand, the elevated glucose serum concentrations were found as a strong determinant of b2-m serum levels in dialysis patients, thus a better glycemic control

10 538 F. S. AMIRI ET AL. in combination to a better b2-m clearance that obtained by a good dialysis adequacy should be very beneficial for this population of patients and resulting in downregulation of inflammation. b2-m downstream signaling regulates androgen receptor (AR) and PSA expression directly in AR positive prostate cancer cells. In both ARpositive and AR-negative prostate cancer cells, interrupting b2-m signaling with the b2-m antibody inhibited cancer cell growth and induced its apoptosis. The b2-m antibody is a novel and promising therapeutic agent for the treatment of human prostate cancers. 51 The usefulness of b2-m as tumor marker is limited in the presence of CKD, since the impairment of renal function may increase b2-m levels in an unpredictable way. In this case when using b2-m as a tumor marker, it is appropriate to adjust its values for the degrees of deterioration of renal function calculated with GFR. 3 Human chorionic gonadotropin in chronic kidney disease Human chorionic gonadotropin (HCG), a marker of germ cell tumors and trophoblastic disease, is 45KD glycoprotein, composed of two dissimilar subunits of the alpha chain (14 KD) and beta chain (24KD). It contains 30% carbohydrate. The beta subunit (b-subunit) determines immunological and hormone specificity. HCG is synthesized by the syncytiotrophoblasts of the placenta during pregnancy. The reference values in serum of healthy men and non-pregnant women are less than 5 IU/L and post-menopausal women are less than 10 IU/L. HCG shows 100% sensitivity for choriocarcinoma irrespective of their site in addition to hydatidiform mole. In testicular tumors, the detection of HCG and AFP correlates with the histological findings, and is therefore crucial for the therapeutic procedures with the use of serial determinations of b-hcg, because the biochemical recurrence precedes by 3 months before the patient has symptoms of clinical recurrence/metastases. The tumor marker also helps in monitoring high-risk group of testicular tumors especially individuals with undescended testicle or the healthy monozygotic twin of a testicular tumor patient. High levels of b-hcg indicate poor prognosis and frequent assays of HCG level during therapy are correlated to the clinical response. Serum HCG levels are rarely elevated in non-trophoblastic tumors, such as lung, breast, pancreas, and bladder cancers. 25 Half-life of it in serum is approximately16-24 h, decline of serum levels may be biphasic with a second t½ of 12.8 days. 29 The role of chronic kidney disease (CKD) as a cause of elevated HCG levels has not been studied. It is well-known that 30% of HCG being produced is cleared by the kidney and an additional fraction metabolized by it. Retrospective study performed by Soni et al., 52 reported a series of 5 women out of 62 with CKD, who had a positive HCG (5 IU/L) test on routine pre-transplant screening at a single transplant center. In this cohort of female CKD patients, HCG levels 45 IU/L were observed in 5/62 (8.1%). The presence of CKD may cause to elevate the further HCG levels in patients. Despite aggressive investigation, their elevated HCG levels remained unexplained. The positive test contributed to delays in transplantation and increased overall cost of treatment. A case report showed persistent elevation of b-hcg levels in a patient with stage 5D chronic kidney disease. Elevated b-hcg could be attributed to a tumor of gestational or non-gestational origin, failed pregnancy, familial high HCG, reduced clearance, and degradation of HCG in CKD or CKDassociated changes of HCG. Immunoassay interference should be considered when patient results and clinical presentation differs. False positive test results may subject patients to unnecessary investigation and it may prevent patients from qualifying for organ transplantation. 53 Carcinoembryonic antigen in CKD Carcinoembryonic antigen (CEA), first described in 1965, was characterized as glycoproteins of 200 kda. It is excreted by certain embryonic and adult tissues in addition to adenocarcinoma of the digestive organs. Extensive studies of patients bearing primary and metastatic colorectal neoplasms have determined that its primary use is in the detection of local and metastatic cancer recurrence after initial resection of the primary tumor, through periodic post-operative analysis of CEA in serum or plasma. Clinical studies showed that CEA, although originally thought to be specific for digestive tract cancers, may also be elevated in other malignancies and in some non-malignant disorders. CEA testing has significant value in the monitoring of patients with diagnosed malignancies in whom changing concentrations of CEA are observed. A persistent elevation in circulating CEA following treatment is strongly indicative of occult metastatic and/or residual disease. A persistently rising CEA value may be associated with progressive malignant disease and a poor therapeutic response. A declining CEA value is generally indicative of a favorable prognosis and a good response to treatment. Patients who have low pretreatment CEA levels may later show elevations in the CEA level as an indication of progressive disease. Follow-up studies of patients with colorectal, breast, and lung carcinoma suggest that the pre-operative CEA level has prognostic significance. CEA testing is not recommended as a screening procedure to

11 RENAL FAILURE 539 detect cancer in the general population; however, use of the CEA test as an adjunctive test in predicting prognosis and as an aid in the management of cancer patients has been widely accepted. 25 Levels of CA 125, Carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), neuron-specific enolase (NSE) can be falsely elevated and have to be interpreted with caution. 30 CEA levels typically return to normal within four to six weeks after successful surgical resection. The major role for CEA levels is in following patients for relapse after intended curative treatment of colorectal cancer. When patients with a normal pre-operative CEA level have cancer recurrence, CEA elevation is a sign in nearly one half of them. The American Society of Clinical Oncology recommends monitoring CEA levels every two to three months for at least two years in patients with stage II or III disease who are surgical candidates. 54 Although carcinoembryonic antigen and CA 19-9 have been proposed for use of gastric cancer and squamous cell carcinoma antigen for use in cervical cancer, none of these markers can currently be recommended for routine clinical use. 55 The combination of CEA and b2- M determination proved to be most useful in cases of non-small cell lung carcinoma and for follow up of cases. Serial determination of the CEA is recommended with each course of treatment to help in predicting patient s response and monitoring the disease. 56 Carcinoembryonic antigen (CEA) was estimated in plasma from 70 patients with a renal transplant, 105 patients with glomerulonephritis who had received immunosuppressive therapy, and 124 healthy controls. There were raised levels in 30% of those with a renal transplant, 10% of those with glomerulonephritis, and 2% of controls, and levels were higher in current smokers. CEA levels correlated neither with prednisolone dosage nor with number of rejection episodes, after allowing for time after transplantation and smoking habit. Nine of 70 patients with a renal transplant and three of 105 with glomerulonephritis had cancer as skin in seven, cervix uteri in four, and colon in one. CEA was raised in all of four transplant recipients with a visceral cancer (three cervical cancers and one colon cancer), but did not rise in any of the five patients with cutaneous cancer. Raised CEA levels occurring late after a renal allograft should prompt a careful search for visceral cancer. 57 Furthermore, serum CEA concentrations strongly tend to duplicate after HD treatment. 22 In a study by Bo, 58 the diagnostic value of CEA, CA l9-9, NSE, CA 125 in tumors of maintenance hemodialysis patients were decreased, and the detection and diagnostic value of tumor markers of CA 242, CA l53, b-hcg, AFP, human growth hormone (HGH), PSA, fpsa were normal. Additionally, an elevated CEA level in the patients with severe bowel inflammation, such as complicated pseudomembranous colitis (PMC) can be correlated with inflammation. 59 The presence of extramedullary involvement in multiple myeloma (MM) patients is a rare clinical manifestation, found in only 4.6% of cases. Talamo et al., 60 reported a case of rectal involvement by MM in which the malignant plasma cells produced serum carcinoembryonic antigen (CEA), a tumor marker more commonly associated with rectal adenocarcinomas. Chromogranin A in chronic kidney disease Granins are proteins found in dense core secretory granules of most endocrine and non-endocrine cells as well as central and peripheral neurons. There are two subfamilies: chromogranins, mainly A and B and secretogranins II to VI. Secretogranins I and II are also known as CgB and CgC. 61 Chromogranin A belonging to the group of closely related secretory acidic proteins is used as a tumor marker to assess exocytotic sympathoadrenal activity in Pheochromocytoma patients. Its concentrations in plasma are elevated in peptide producing tumors. 25 Chromogranin A (CgA) is a 49 kda acidic hydrophilic protein synthesized in the chromaffin granules of the neuroendocrine cells and is traceable in the blood of healthy subjects at concentrations of less than 30 ng/ml. Elevated levels of CgA in serum are detectable in patients affected by neuroendocrine (NE) or carcinoid tumors, pheochromocytoma, neuroblastoma, small cell lung cancer (SCLC), and prostate cancer. 3 Recently, CgA has known as a useful biomarker in hepatocellular carcinoma (HCC) screening, representing a complementary test when the levels of a-fp are not sufficiently diagnostic (5200 ng/ml). Serum CgA determination can also be used to predict the progression or regression of neuroendocrine tumors during the treatment. However, CgA elevation has been rarely reported in patients without cancerous conditions, such as essential hypertension, so that the possibility of false positive results should be considered. CgA is the most ubiquitous and sensitive general marker for the diagnosis of endocrine tumors. In a study by Kurnatowska et al., 62 plasma CgA and blood pressure of 38 chronic hemodialysis patients were measured before and after a mid-week dialysis. Plasma CgA levels were on average 50-fold higher in HD patients than in the controls. In HD patients, plasma CgA corrected for ultrafiltration rates that were significantly increased at the end of dialysis procedure. Therefore, CgA undergoes marked accumulation in renal failure. 63 Awadallah et al., 64 revealed that the application of CgA as a tumor marker in the diagnosis of hepatocellular carcinoma (HCC) is to be considered especially in cases

12 540 F. S. AMIRI ET AL. with low levels of AFP, as determination of CgA serum values represents a complementary diagnostic tool in monitoring of chronic liver disease patients for detection of HCC. The combined use of both CgA and AFP to detect HCC increases their sensitivity and specificity. Chromogranin A is released with epinephrine and norepinephrine from catecholaminergic cells. Specific endopeptidases cleave chromogranin A into biologically active peptide fragments, including catestatin, which inhibits catecholamine release. Previous studies have suggested that a deficit in this sympathetic braking system might be an early event in the pathogenesis of human hypertension. Circulating levels of catestatin were lower among those with hypertensive end-stage renal disease (ESRD) than controls, an unexpected finding given that peptide levels are usually elevated in ESRD because of reduced renal elimination. So, common variants in chromogranin A associate with the risk of hypertensive ESRD in blacks. 65 High serum levels of CgA have also been demonstrated in patients with ovarian cancer. The abnormal productions of CgA suggest that this circulating glycoprotein can indeed affect several aspects of the complex interplay between tumor-associated vessels and neoplastic cells. According to previous studies, Catania et al., 66 found that CgA depicted a significant trend in association with high-grade disease. Wise-Draper et al. 67 reported a case of 78-year-old male with a high-grade post-transplant lymphoproliferative disorder (PTLD) and metastatic pancreatic neuroendocrine tumor (PNET) about 14 years after kidney transplantation. To evaluate oxidative stress and CgA levels in uremia and dialysis, study showed that uremia is the major source of the increase in oxidative stress and CgA levels in patients with end-stage renal disease. 68 Other tumor markers C-reactive protein (CRP) is an acute phase protein synthesized by hepatocytes in the liver in response to interleukin-6 (IL-6) cytokine induction according to inflammatory process as a result of a host immune response. The present results suggest that CRP levels are a more consistent indicator of cancer risk than some tumor markers. Furthermore, the association between cancer incidence and CRP as an inflammatory marker may be tumor type specific and increased level of CRP may show a stronger association with risk of cancer incidence, recurrence, and death. 69 Trefoil factor family (TFF) members are small secreted proteins that are coexpressed with mucins by the epithelial cells lining the gastrointestinal tract. Serum and urine TFF3 levels were significantly higher in the patients with gastric and colorectal cancer compared with the healthy individuals. Data demonstrated that serum TFF3 can be applied as an effective biomarker for the detection of tumor stages, distant metastasis, and pharmacodynamic marker of responses to chemotherapy in gastrointestinal cancer. Urine TFF3 is a different indicator than serum levels and could also be a biomarker for the early detection of renal dysfunction. 70 Elevated levels of serum gastrin (SG) have been associated with tumorigenic effects in a number of gastrointestinal cancers. A high SG level (480 pg/ml), intestinal metaplasia, and a pepsinogen I/II ratio53 were independently associated with an increased risk of epithelial lesions. 71 Cytokeratin fragment 21-1 is an antigenic determinant present on 40 KD protein of the cytokeratin 19. This antigen is expressed in normal, simple epithelium as well as in proliferating epithelium. Cyfra 21-1 is used as a tumor marker for non-small cell lung cancer (NSCLC), such as squamous cell carcinoma (SCC), adenocarcinoma and large cell carcinomas. This tumor marker shows highest sensitivity for SCC in lung. Both Cyfra 21-1 and CA 19-9 have improved the sensitivity for the detection of adenocarcinoma of lung. 25 CA 549 is a high molecular weight circulating glycoprotein antigen associated with breast cancer. Elevated levels of CA 549 are observed in serum of advanced breast cancer by immunoassay. However, use of CA 19-5 and CA 50 together improves sensitivity in detecting pancreatic and other carcinomas. Tissue polypeptide antigen (TPA), which is regarded as a marker of cell proliferation, is a mixture of proteolytic fragments containing the relatively stable a-helical rod domains of simple epithelium-type cytokeratin. The marked elevation of serum TPA is reported in variety of cancers, such as breast, lung, gastrointestinal, urological, gynecological cancer. TPA is known to be a sensitive but non-specific tumor marker. However, TPA along with CEA uses as aid for monitoring of lung, bladder, breast, colorectal, and ovarian carcinomas. TPA is also reported to differentiate between cholangiocarcinoma and hepatocarcinomas. Calcitonin, a low molecular weight circulating peptide hormone, that synthesized by C cells of the thyroid, is used as tumor marker and its increased concentration is reported in malignancies with skeletal metastases. Serum calcitonin concentrations are also reported to increase in medullary carcinoma of the thyroid, bronchogenic carcinoma, small cell lung cancer, breast, liver, lung, renal cancers, and carcinoid tumors. Catecholamines, Cathepsin D, epidermal growth factor receptor (EGFR), estrogen receptor (ER), progesterone receptor (PR), ferritin, homovanillic acid (HVA) and vanillylmandelic acid (VMA), hydroxyindoleacetic acid (5-HIAA), interleukin 2 receptor/tac antigen (IL-2R), lipidassociated sialic acid in plasma (LASA-P), neuron-specific

Tumour Markers. For these reasons, only a handful of tumour markers are commonly used by most doctors.

Tumour Markers. For these reasons, only a handful of tumour markers are commonly used by most doctors. Tumour Markers What are Tumour Markers? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer

More information

TUMOR M ARKERS MARKERS

TUMOR M ARKERS MARKERS TUMOR MARKERS M.Shekarabi IUMS Definition Many cancers are associated with the abnormal production of some molecules l which h can be measured in plasma. These molecules are known as tumor markers. A good

More information

Fast, automated, precise

Fast, automated, precise Thermo Scientific B R A H M S / NSE Immunodiagnostic Assays Fast, automated, precise Neuroendocrine tumor markers on KRYPTOR Systems First and only fully automated CgA assay worldwide Shortest time to

More information

Tumor Markers Yesterday, Today & Tomorrow. Steven E. Zimmerman M.D. Vice President & Chief Medical Director

Tumor Markers Yesterday, Today & Tomorrow. Steven E. Zimmerman M.D. Vice President & Chief Medical Director Tumor Markers Yesterday, Today & Tomorrow Steven E. Zimmerman M.D. Vice President & Chief Medical Director Tumor Marker - Definition Substances produced by cancer cells or other cells in response to cancer

More information

Dr. Shari Srinivasan, Consultant Chemical Pathologist, Tallaght Hospital, Dublin 24, Ireland

Dr. Shari Srinivasan, Consultant Chemical Pathologist, Tallaght Hospital, Dublin 24, Ireland Draft Laboratory Testing for Tumour Markers V1.0 Authors Dr. Shari Srinivasan, Consultant Chemical Pathologist, Tallaght Hospital, Dublin 24, Ireland Dr. Gerard Boran, Consultant Chemical Pathologist,

More information

Clinical Biochemistry Department City Hospital

Clinical Biochemistry Department City Hospital Cancer Biochemistry and Tumour Markers Clinical Biochemistry Department City Hospital In this lecture Cancer basics Definition of Tumour Marker (TM) What is the perfect TM? History of TMs Examples of TMs

More information

EDUCATIONAL COMMENTARY CA 125. Learning Outcomes

EDUCATIONAL COMMENTARY CA 125. Learning Outcomes EDUCATIONAL COMMENTARY CA 125 Learning Outcomes Upon completion of this exercise, participants will be able to: discuss the use of CA 125 levels in monitoring patients undergoing treatment for ovarian

More information

Tumor Immunology. Tumor (latin) = swelling

Tumor Immunology. Tumor (latin) = swelling Tumor Immunology Tumor (latin) = swelling benign tumor malignant tumor Tumor immunology : the study of the types of antigens that are expressed by tumors how the immune system recognizes and responds to

More information

Tumor Markers & Cytopathology

Tumor Markers & Cytopathology Tumor Markers & Cytopathology Objectives: After learning, student should be able to 1. Describe the basic concepts of tumor markers and Asst. Prof. Prasit Suwannalert, Ph.D. (Email: prasit.suw@mahidol.ac.th)

More information

-The cause of testicular neoplasms remains unknown

-The cause of testicular neoplasms remains unknown - In the 15- to 34-year-old age group, they are the most common tumors of men. - include: I. Germ cell tumors : (95%); all are malignant. II. Sex cord-stromal tumors: from Sertoli or Leydig cells; usually

More information

Note: The cause of testicular neoplasms remains unknown

Note: The cause of testicular neoplasms remains unknown - In the 15- to 34-year-old age group, they are the most common tumors of men. - Tumors of the testis are a heterogeneous group of neoplasms that include: I. Germ cell tumors : 95%; all are malignant.

More information

Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC

Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,

More information

PRODUCT I N FOR MATION Fujirebio Diagnostics EIA Kit

PRODUCT I N FOR MATION Fujirebio Diagnostics EIA Kit PRODUCT I N FOR MATION Fujirebio Diagnostics EIA Kit Only available outside the US Working Together for Better Diagnostics Introduction Features and Benefits of EIA kits from Fujirebio Diagnostics Simple

More information

Thermo Scientific B R A H M S Biomarkers Tumor Marker Assays. Excellent precision. Confident cancer monitoring

Thermo Scientific B R A H M S Biomarkers Tumor Marker Assays. Excellent precision. Confident cancer monitoring Thermo Scientific B R A H M S Biomarkers Tumor Marker Assays Excellent precision Confident cancer monitoring Thermo Scientific B R A H M S Biomarkers Tumor Markers Parameter Clinical Interest Product Technology

More information

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management. Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician

More information

Critical Raw Materials. Critical Raw Materials. Cell Culture Derived Antigens and Antibodies

Critical Raw Materials. Critical Raw Materials. Cell Culture Derived Antigens and Antibodies Critical Raw Materials Critical Raw Materials Cell Culture Derived Antigens and Antibodies Critical Raw Materials Antigens and antibodies for tumor markers, pituitary hormones, cardiac markers and fertility

More information

Tumor Markers. Units: U/ml Ref.- range: <35.0

Tumor Markers. Units: U/ml Ref.- range: <35.0 Tumor Markers CA 125 The CA 125 (carbohydrate antigen 12-5) is a glycolipoprotein with a high molecular weight of 1000 kd. CA 125 is found in fetal and adult normal tracheal, bronchial, bronchiolar and

More information

Tumor markers. Chromogranin A. Analyte Information

Tumor markers. Chromogranin A. Analyte Information Tumor markers Chromogranin A Analyte Information -1-2018-04-22 Chromogranin A Introduction Chromogranin A (CgA) is a 439-amino acid protein with a molecular weight of 48 to 60 kda, depending on glycosylation

More information

BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Cancer is a group of more than 100 different diseases that are characterized by uncontrolled cellular growth,

More information

Human epididymal protein 4 The role of HE4 in the management of patients presenting with pelvic mass Publication abstracts

Human epididymal protein 4 The role of HE4 in the management of patients presenting with pelvic mass Publication abstracts Human epididymal protein 4 The role of HE4 in the management of patients presenting with pelvic mass Publication abstracts Ovarian cancer is diagnosed annually in more than 200,000 women worldwide, with

More information

Tumor Markers. Units: U/ml Ref.- range: <35.0

Tumor Markers. Units: U/ml Ref.- range: <35.0 Tumor Markers CA 125 The CA 125 (carbohydrate antigen 12-5) is a glycolipoprotein with a high molecular weight of 1000 kd. CA 125 is found in fetal and adult normal tracheal, bronchial, bronchiolar and

More information

3 Summary of clinical applications and limitations of measurements

3 Summary of clinical applications and limitations of measurements CA125 (serum) 1 Name and description of analyte 1.1 Name of analyte Cancer Antigen 125 (CA125) 1.2 Alternative names Mucin-16 1.3 NLMC code To follow 1.4 Description of analyte CA125 is an antigenic determinant

More information

Bihong Zhao, M.D, Ph.D Department of Pathology

Bihong Zhao, M.D, Ph.D Department of Pathology Bihong Zhao, M.D, Ph.D Department of Pathology 04-28-2009 Is tumor self or non-self? How are tumor antigens generated? What are they? How does immune system respond? Introduction Tumor Antigens/Categories

More information

COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16

COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand

More information

Tumour Markers as screening tests for cancer: is it practical?

Tumour Markers as screening tests for cancer: is it practical? Tumour Markers as screening tests for cancer: is it practical? Dr Tong SF MBBS (UM) MMed (Fam Med) (UKM) PhD (Sydney) Department of Family Medicine Faculty of Medicine UKM Is it practical for? Detecting

More information

PRODUCT INFORMATION Fujirebio Diagnostics EIA Kit

PRODUCT INFORMATION Fujirebio Diagnostics EIA Kit PRODUCT INFORMATION Fujirebio Diagnostics EIA Kit Only available outside the US Future. The best way to predict the future is to create it. Only by truly understanding the needs of patients, and by collaborating

More information

Biochemistry of Cancer and Tumor Markers

Biochemistry of Cancer and Tumor Markers Biochemistry of Cancer and Tumor Markers The term cancer applies to a group of diseases in which cells grow abnormally and form a malignant tumor. It is a long term multistage genetic process. The first

More information

Doppler ultrasound of the abdomen and pelvis, and color Doppler

Doppler ultrasound of the abdomen and pelvis, and color Doppler - - - - - - - - - - - - - Testicular tumors are rare in children. They account for only 1% of all pediatric solid tumors and 3% of all testicular tumors [1,2]. The annual incidence of testicular tumors

More information

Diabetes. Albumin. Analyte Information

Diabetes. Albumin. Analyte Information Diabetes Albumin Analyte Information -1-2014-05-02 Albumin Introduction Albumin consists of a single polypeptide chain of 585 amino acids with molecular weight of 66.5 kda. The chain is characterized by

More information

MARTIN FLEISHER, PH.D., FACB MEMORIAL SLOAN-KETTERING CANCER CENTER NEW YORK, N.Y.

MARTIN FLEISHER, PH.D., FACB MEMORIAL SLOAN-KETTERING CANCER CENTER NEW YORK, N.Y. MARTIN FLEISHER, PH.D., FACB MEMORIAL SLOAN-KETTERING CANCER CENTER NEW YORK, N.Y. FLEISHEM@MSKCC.ORG The Ideal Tumor Marker Quantitative level of TM reflects tumor burden with high diagnostic sensitivity

More information

Medical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University

Medical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve

More information

Personalized Medicine: Home Test Kit for Cancer

Personalized Medicine: Home Test Kit for Cancer Personalized Medicine: Home Test Kit for Cancer Joanne I. Yeh, Ph.D Associate Professor, Department of Structural Biology, University of Pittsburgh; Associate Professor, Department of Bioengineering, University

More information

Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression

Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Mona A. Abd-Elazeem, Marwa A. Abd- Elazeem Pathology department, Faculty of Medicine, Tanta

More information

Non-protein nitrogenous substances (NPN)

Non-protein nitrogenous substances (NPN) Non-protein nitrogenous substances (NPN) A simple, inexpensive screening test a routine urinalysis is often the first test conducted if kidney problems are suspected. A small, randomly collected urine

More information

Workup of a Solid Liver Lesion

Workup of a Solid Liver Lesion Workup of a Solid Liver Lesion Joseph B. Cofer MD FACS Chief Quality Officer Erlanger Health System Affiliate Professor of Surgery UTHSC-Chattanooga I have no financial or other relationships with any

More information

4100: Cellular Therapy Essential Data Follow-Up Form

4100: Cellular Therapy Essential Data Follow-Up Form 4100: Cellular Therapy Essential Data Follow-Up Form Registry Use Only Sequence Number: Date Received: Key Fields CIBMTR Center Number: Event date: Visit: 100 day 6 months 1 year 2 years >2 years, Specify:

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Chacón MR, Enrico DH, Burton J, Waisberg FD, Videla VM. Incidence of placebo adverse events in randomized clinical trials of targeted and immunotherapy cancer drugs in the

More information

Pancreas Quizzes c. Both A and B a. Directly into the blood stream (not using ducts)

Pancreas Quizzes c. Both A and B a. Directly into the blood stream (not using ducts) Pancreas Quizzes Quiz 1 1. The pancreas produces hormones. Which type of hormone producing organ is the pancreas? a. Endocrine b. Exocrine c. Both A and B d. Neither A or B 2. Endocrine indicates hormones

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Serum Tumor Markers for Breast Malignancies Page 1 of 9 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Serum Tumor Markers for Breast Malignancies Professional

More information

Monitoring Patients Undergoing Cancer Therapy. By Timothy K. Egan

Monitoring Patients Undergoing Cancer Therapy. By Timothy K. Egan F E A T U R E By Timothy K. Egan Before placement in a computed tomography scanner, a patient is fitted with an immobilization device. Immobilization ensures that the same area of the patient is scanned

More information

MEDICAL POLICY SUBJECT: SERUM TUMOR MARKERS FOR DIAGNOSIS AND MANAGEMENT OF CANCER. POLICY NUMBER: CATEGORY: Laboratory Test

MEDICAL POLICY SUBJECT: SERUM TUMOR MARKERS FOR DIAGNOSIS AND MANAGEMENT OF CANCER. POLICY NUMBER: CATEGORY: Laboratory Test MEDICAL POLICY SUBJECT: SERUM TUMOR MARKERS FOR 09/18/08, 09/17/09 PAGE: 1 OF: 10 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial

More information

Neoplasia part I. Dr. Mohsen Dashti. Clinical Medicine & Pathology nd Lecture

Neoplasia part I. Dr. Mohsen Dashti. Clinical Medicine & Pathology nd Lecture Neoplasia part I By Dr. Mohsen Dashti Clinical Medicine & Pathology 316 2 nd Lecture Lecture outline Review of structure & function. Basic definitions. Classification of neoplasms. Morphologic features.

More information

Carcinoembryonic Antigen

Carcinoembryonic Antigen Other Names/Abbreviations CEA 190.26 - Carcinoembryonic Antigen Carcinoembryonic antigen (CEA) is a protein polysaccharide found in some carcinomas. It is effective as a biochemical marker for monitoring

More information

Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar

Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar Link full download:https://getbooksolutions.com/download/test-bank-for-robbinsand-cotran-pathologic-basis-of-disease-9th-edition-by-kumar Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th

More information

Diabetes Mellitus and Breast Cancer

Diabetes Mellitus and Breast Cancer Masur K, Thévenod F, Zänker KS (eds): Diabetes and Cancer. Epidemiological Evidence and Molecular Links. Front Diabetes. Basel, Karger, 2008, vol 19, pp 97 113 Diabetes Mellitus and Breast Cancer Ido Wolf

More information

What is the Impact of Cancer on African Americans in Indiana? Average number of cases per year. Rate per 100,000. Rate per 100,000 people*

What is the Impact of Cancer on African Americans in Indiana? Average number of cases per year. Rate per 100,000. Rate per 100,000 people* What is the Impact of Cancer on African Americans in Indiana? Table 13. Burden of Cancer among African Americans Indiana, 2008 2012 Average number of cases per year Rate per 100,000 people* Number of cases

More information

Name of Policy: Serum Tumor Markers for Breast and Gastrointestinal Malignancies

Name of Policy: Serum Tumor Markers for Breast and Gastrointestinal Malignancies Name of Policy: Serum Tumor Markers for Breast and Gastrointestinal Malignancies Policy #: 195 Latest Review Date: October 2013 Category: Medical Policy Grade: A Background/Definitions: As a general rule,

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hematopoietic Stem-Cell Transplantation in the Treatment of Germ File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_in_the_treatment_of_germ_cell_tumor

More information

Surgical Management of Pulmonary Metastases. Dr AG Jacobs Principal Specialist Dept Cardiothoracic Surgery Steve Biko Academic Hospital

Surgical Management of Pulmonary Metastases. Dr AG Jacobs Principal Specialist Dept Cardiothoracic Surgery Steve Biko Academic Hospital Surgical Management of Pulmonary Metastases Dr AG Jacobs Principal Specialist Dept Cardiothoracic Surgery Steve Biko Academic Hospital Introduction Lungs 2 nd most common site of metastatic deposition

More information

3 cell types in the normal ovary

3 cell types in the normal ovary Ovarian tumors 3 cell types in the normal ovary Surface (coelomic epithelium) the origin of the great majority of ovarian tumors (neoplasms) 90% of malignant ovarian tumors Totipotent germ cells Sex cord-stromal

More information

Skeletal. Parathyroid hormone-related protein Analyte Information

Skeletal. Parathyroid hormone-related protein Analyte Information Skeletal Parathyroid hormone-related protein Analyte Information 1 2012-04-04 Parathyroid hormone related protein (PTHrP) Introduction Parathyroid hormone-related protein (PTHrP) is actually a family of

More information

Gynecologic Cancer Surveillance and Survivorship: Informing Practice and Policy

Gynecologic Cancer Surveillance and Survivorship: Informing Practice and Policy Gynecologic Cancer Surveillance and Survivorship: Informing Practice and Policy Stephanie Yap, M.D. University Gynecologic Oncology Northside Cancer Institute Our Learning Objectives Review survival rates,

More information

Ontario s Referral and Listing Criteria for Adult Kidney Transplantation

Ontario s Referral and Listing Criteria for Adult Kidney Transplantation Ontario s Referral and Listing Criteria for Adult Kidney Transplantation Version 3.0 Trillium Gift of Life Network Adult Kidney Transplantation Referral & Listing Criteria PATIENT REFERRAL CRITERIA: The

More information

Tumor Markers: Granular Analysis of the US Market Supplier Shares and Forecasts for 40 Cancer Diagnostic Tests. List of Tables

Tumor Markers: Granular Analysis of the US Market Supplier Shares and Forecasts for 40 Cancer Diagnostic Tests. List of Tables Tumor Markers: Granular Analysis of the US Market Supplier Shares and Forecasts for 40 Cancer Diagnostic Tests List of Tables Tumor Marker Classification ACTH Tests AFP Tests Beta-2 Microglobulin Tests

More information

Transplant Hepatology

Transplant Hepatology Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified

More information

Type 2 Diabetes and Cancer: Is there a link?

Type 2 Diabetes and Cancer: Is there a link? Type 2 Diabetes and Cancer: Is there a link? Sonali Thosani, MD Assistant Professor Department of Endocrine Neoplasia & Hormonal Disorders MD Anderson Cancer Center No relevant financial disclosures Objectives

More information

Clinical Significance of Elevated -Fetoprotein in Adults and Children

Clinical Significance of Elevated -Fetoprotein in Adults and Children , pp. 1709 1713 Clinical Significance of Elevated -Fetoprotein in Adults and Children RANDEEP KASHYAP,* ASHOK JAIN, MD,* MICHAEL NALESNIK, BRIAN CARR,* JACKIE BARNES,* HUGO E. VARGAS, JORGE RAKELA, and

More information

Oncology 101. Cancer Basics

Oncology 101. Cancer Basics Oncology 101 Cancer Basics What Will You Learn? What is Cancer and How Does It Develop? Cancer Diagnosis and Staging Cancer Treatment What is Cancer? Cancer is a group of more than 100 different diseases

More information

Immunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Immunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate

More information

Chronic Kidney Disease (CKD) Stages. CHRONIC KIDNEY DISEASE Treatment Options. Incident counts & adjusted rates, by primary diagnosis Figure 2.

Chronic Kidney Disease (CKD) Stages. CHRONIC KIDNEY DISEASE Treatment Options. Incident counts & adjusted rates, by primary diagnosis Figure 2. Chronic Kidney Disease (CKD) Stages Stage 1 GFR > 90 (evidence of renal disease) Stage 2 GFR 60-89 Stage 3 GFR 30-59 Stage 4 GFR 15-29 Stage 5 GFR

More information

FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center

FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center 1430 Tulane Ave., Box SL-68, New Orleans, LA 70112-2699 J. Bennett Johnston Building, Mezzanine (Floor 1A), Suite A102 (504) 988-6060, fax (504) 988-6077,

More information

Burden of Cancer in California

Burden of Cancer in California Burden of Cancer in California California Cancer Reporting and Epidemiologic Surveillance Institute for Population Health Improvement UC Davis Health August 22, 2018 Outline 1. Incidence and Mortality

More information

We are gong to focus on: Unit 9. Before we begin: Chronic Renal Failure/Uremia ESRD/Dialysis Prostate Cancer Testicular Cancer Renal Cancer

We are gong to focus on: Unit 9. Before we begin: Chronic Renal Failure/Uremia ESRD/Dialysis Prostate Cancer Testicular Cancer Renal Cancer Unit 9 Problems with excretion Before we begin: You are to understand on your own: A & P of Renal System Common terms of renal system How to perform a focused health history How to perform a Physical Exam

More information

Neoplasias Quisticas del Páncreas

Neoplasias Quisticas del Páncreas SEAP -Aproximación Práctica a la Patología Gastrointestinal- Madrid, 26 de mayo, 2006 Neoplasias Quisticas del Páncreas Gregory Y. Lauwers, M.D. Director, Service Massachusetts General Hospital Harvard

More information

Management of HBV in KidneyTransplanted Patients Dr.E.Nemati

Management of HBV in KidneyTransplanted Patients Dr.E.Nemati Management of HBV in KidneyTransplanted Patients Dr.E.Nemati Hepatitis B virus (HBV) infection Hepatitis B virus (HBV) infection confers a significantly negative impact on the clinical outcomes of kidney

More information

Is It Time To Implement Ovarian Cancer Screening?

Is It Time To Implement Ovarian Cancer Screening? Is It Time To Implement Ovarian Cancer Screening? Prof Dr Samet Topuz Istanbul Medıcal Faculty Department Of Obstetrics and Gynecology ESGO Prevention in Gynaecological Malignancies September 08 2016 Antalya

More information

Diagnostic IHC in lung and pleura pathology

Diagnostic IHC in lung and pleura pathology Diagnostic IHC in lung and pleura pathology Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark WHO 2004 and Web Malignant mesothelioma Epithelioid

More information

S2 File. Clinical Classifications Software (CCS). The CCS is a

S2 File. Clinical Classifications Software (CCS). The CCS is a S2 File. Clinical Classifications Software (CCS). The CCS is a diagnosis categorization scheme based on the ICD-9-CM that aggregates all diagnosis codes into 262 mutually exclusive, clinically homogeneous

More information

TDM. Measurement techniques used to determine cyclosporine level include:

TDM. Measurement techniques used to determine cyclosporine level include: TDM Lecture 15: Cyclosporine. Cyclosporine is a cyclic polypeptide medication with immunosuppressant effect. It has the ability to block the production of interleukin-2 and other cytokines by T-lymphocytes.

More information

Major tips: The importance of early detection: Hx, risk factors

Major tips: The importance of early detection: Hx, risk factors Cancer Chapter 3 Introduction Cancer ranks 2nd to cardiovascular disease as the leading cause of death in the Gaza Strip. Death rate increased from 10.3% in 2007 to 13.6 in 2012. Some related factors :

More information

4/20/2015. Serum Protein Tumor Marker Assays: A Need for Constant Vigilance. Learning Objectives. Estimated Cancer Deaths in the US in 2015

4/20/2015. Serum Protein Tumor Marker Assays: A Need for Constant Vigilance. Learning Objectives. Estimated Cancer Deaths in the US in 2015 Serum Protein Tumor Marker Assays: A Need for Constant Vigilance Nichole Korpi-Steiner, PhD, DABCC, FACB University of North Carolina Chapel Hill, NC Learning Objectives Describe what comprises an ideal

More information

BIOLOGY OF CANCER. Definition: Cancer. Why is it Important to Understand the Biology of Cancer? Regulation of the Cell Cycle 2/13/2015

BIOLOGY OF CANCER. Definition: Cancer. Why is it Important to Understand the Biology of Cancer? Regulation of the Cell Cycle 2/13/2015 BIOLOGY OF CANCER Why is it Important to Understand the Biology of Cancer? Cynthia Smith, RN, BA, MSN, AOCN Oncology Clinical Nurse Specialist Harrison Medical Center Definition: Cancer Regulation of the

More information

HLA and antigen presentation. Department of Immunology Charles University, 2nd Medical School University Hospital Motol

HLA and antigen presentation. Department of Immunology Charles University, 2nd Medical School University Hospital Motol HLA and antigen presentation Department of Immunology Charles University, 2nd Medical School University Hospital Motol MHC in adaptive immunity Characteristics Specificity Innate For structures shared

More information

Neoplasms of the Canine, Feline and Lemur Liver:

Neoplasms of the Canine, Feline and Lemur Liver: Neoplasms of the Canine, Feline and Lemur Liver: Classification and Prognosis Annual Seminar of the French Society of Veterinary Pathology John M. Cullen VMD PhD DACVP North Carolina State University Primary

More information

Immunology CANCER IMMUNOLOGY

Immunology CANCER IMMUNOLOGY Immunology د. عائدة الدرزي Lec. 6 CANCER IMMUNOLOGY Oncogenesis (passes through two stages): 1- Reversible change Normal transformed cells 2- Irreversible change Transformed oncogenic cells Factors causing

More information

Post Transplant Immunosuppression: Consideration for Primary Care. Sameh Abul-Ezz, M.D., Dr.P.H.

Post Transplant Immunosuppression: Consideration for Primary Care. Sameh Abul-Ezz, M.D., Dr.P.H. Post Transplant Immunosuppression: Consideration for Primary Care Sameh Abul-Ezz, M.D., Dr.P.H. Objectives Discuss the commonly used immunosuppressive medications and what you need to know to care for

More information

CHAPTER 3 DEATHS. Stephen McDonald Leonie Excell Brian Livingston

CHAPTER 3 DEATHS. Stephen McDonald Leonie Excell Brian Livingston CHAPTER 3 DEATHS Stephen McDonald Leonie Excell Brian Livingston DEATHS ANZDATA Registry 2008 Report INTRODUCTION AUSTRALIA NEW ZEALAND The total number of deaths was 1,452 (15.4 deaths per 100 patient

More information

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President

More information

Triage of Ovarian Masses. Andreas Obermair Brisbane

Triage of Ovarian Masses. Andreas Obermair Brisbane Triage of Ovarian Masses Andreas Obermair Brisbane Why Triage? In ovarian cancer, best outcomes for patients can be achieved when patients are treated in tertiary centres by a multidisciplinary team led

More information

Chapter 9, Part 1: Biology of Cancer and Tumor Spread

Chapter 9, Part 1: Biology of Cancer and Tumor Spread PATHOPHYSIOLOGY Name Chapter 9, Part 1: Biology of Cancer and Tumor Spread I. Cancer Characteristics and Terminology Neoplasm new growth, involves the overgrowth of tissue to form a neoplastic mass (tumor).

More information

Exosomal Del 1 as a potent diagnostic marker for breast cancer : A prospective cohort study

Exosomal Del 1 as a potent diagnostic marker for breast cancer : A prospective cohort study GBCC 2017: ABS-0017 Exosomal Del 1 as a potent diagnostic marker for breast cancer : A prospective cohort study Soo Jung Lee 1, Jeeyeon Lee 2, Jin Hyang Jung 2, Ho Yong Park 2, Chan Hyeong Lee 3, Pyong

More information

Are the ESMO guidelines adapted to the elderly? D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium

Are the ESMO guidelines adapted to the elderly? D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium Are the ESMO guidelines adapted to the elderly? D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium Clinical practice guidelines Definition > Systemically developed statements

More information

Are We Ordering Tumor Markers Appropriately?

Are We Ordering Tumor Markers Appropriately? American Journal of Medicine and Medical Sciences 2017, 7(3): 151-155 DOI: 10.5923/j.ajmms.20170703.08 Are We Ordering Tumor Markers Appropriately? K. Deasy 1, S. Saadi 1, F. Ashraf 1, W. Chin 1, J. Gilmore

More information

-1- Pathology Department (code: 0605) Final Exam for Third year students Date: Time allowed: 2 hours. Paper II (75 marks).

-1- Pathology Department (code: 0605) Final Exam for Third year students Date: Time allowed: 2 hours. Paper II (75 marks). -1- BENHA UNIVERSITY FACULTY OF MEDICINE Pathology Department (code: 0605) Final Exam for Third year students Date: 28-5-2011 Time allowed: 2 hours. Paper II (75 marks). Please note that this question

More information

Ontario s Referral and Listing Criteria for Adult Pancreas-After- Kidney Transplantation

Ontario s Referral and Listing Criteria for Adult Pancreas-After- Kidney Transplantation Ontario s Referral and Listing Criteria for Adult Pancreas-After- Kidney Transplantation Version 2.0 Trillium Gift of Life Network Adult Pancreas-After-Kidney Transplantation Referral & Listing Criteria

More information

Cancer of Unknown Primary (CUP) Protocol

Cancer of Unknown Primary (CUP) Protocol 1 Department of Oncology. Cancer of Unknown Primary (CUP) Protocol Version: Document type: Document sponsor Designation Document author [ s] Designation[s] Approving committee / Group Ratified by: Date

More information

Analyte Specimen Demographic Reference Range Units

Analyte Specimen Demographic Reference Range Units Acetone Negative titer Alanine aminotransferase (ALT/SGPT) 10-49 U/L Albumin 3.2-4.8 g/dl Alcohol < 10 Alpha-fetoprotein (AFP) < 1.3-8.1 ng/ml Alkaline phosphatase 0 7 days 7 30 days 1 3 3 6 6 12 1 3 3

More information

Gynaecological Malignancies

Gynaecological Malignancies Gynaecological Malignancies Dr Rodney Itaki Lecturer Anatomical Pathology Discipline University of Papua New Guinea Division of Pathology School of Medicine & Health Sciences Overview Genital tract tumors

More information

Alpha-fetoprotein

Alpha-fetoprotein Other Names/Abbreviations AFP 190.25 - Alpha-fetoprotein Alpha-fetoprotein (AFP) is a polysaccharide found in some carcinomas. It is effective as a biochemical marker for monitoring the response of certain

More information

Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar

Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar Link full download: http://testbankair.com/download/test-bank-for-robbins-cotran-pathologic-basis-of-disease-9th-edition-bykumar-abbas-and-aster Test Bank for Robbins and Cotran Pathologic Basis of Disease

More information

The Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation

The Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation The Panel Approach to Diagnostics Lauren Hopson International Product Specialist Cell Marque Corporation Cell Marque Rocklin, California About Cell Marque: IVD primary antibody manufacturer Distributors

More information

/Webpages/zhang/chinese-full full- program.htm

/Webpages/zhang/chinese-full full- program.htm http://www.ph.ucla.edu/epi/faculty/zhang /Webpages/zhang/chinese-full full- program.htm Cancer Incidence and Mortality and Risk Factors in the World Zuo-Feng Zhang, M.D., Ph.D. Fogarty International Training

More information

Sexual dysfunction of chronic kidney disease. Razieh salehian.md psychiatrist

Sexual dysfunction of chronic kidney disease. Razieh salehian.md psychiatrist Sexual dysfunction of chronic kidney disease Razieh salehian.md psychiatrist Disturbances in sexual function are a common feature of chronic renal failure. Sexual dysfunction is inversely associated with

More information

BK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy

BK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent

More information

One of the commonest gynecological cancers,especially in white Americans.

One of the commonest gynecological cancers,especially in white Americans. Gynaecology Dr. Rozhan Lecture 6 CARCINOMA OF THE ENDOMETRIUM One of the commonest gynecological cancers,especially in white Americans. It is a disease of postmenopausal women with a peak incidence in

More information

The Urinary S. (Chp. 10) & Excretion. What are the functions of the urinary system? Maintenance of water-salt and acidbase

The Urinary S. (Chp. 10) & Excretion. What are the functions of the urinary system? Maintenance of water-salt and acidbase 10.1 Urinary system The Urinary S. (Chp. 10) & Excretion 10.1 Urinary system What are the functions of the urinary system? 1. Excretion of metabolic wastes (urea, uric acid & creatinine) 1. Maintenance

More information

Institute of Pathology First Faculty of Medicine Charles University. Ovary

Institute of Pathology First Faculty of Medicine Charles University. Ovary Ovary Barrett esophagus ph in vagina between 3.8 and 4.5 ph of stomach varies from 1-2 (hydrochloric acid) up to 4-5 BE probably results from upward migration of columnar cells from gastroesophageal junction

More information

The Major Histocompatibility Complex (MHC)

The Major Histocompatibility Complex (MHC) The Major Histocompatibility Complex (MHC) An introduction to adaptive immune system before we discuss MHC B cells The main cells of adaptive immune system are: -B cells -T cells B cells: Recognize antigens

More information

A patient s guide to understanding. Cancer. Screening

A patient s guide to understanding. Cancer. Screening A patient s guide to understanding Cancer Screening Contents 04 06 10 12 Cancer Screening Who Should Go For Cancer Screening 05 Nasopharyngeal Carcinoma Colorectal Cancer 08 Lung Cancer Liver Cancer Breast

More information

HLA and antigen presentation. Department of Immunology Charles University, 2nd Medical School University Hospital Motol

HLA and antigen presentation. Department of Immunology Charles University, 2nd Medical School University Hospital Motol HLA and antigen presentation Department of Immunology Charles University, 2nd Medical School University Hospital Motol MHC in adaptive immunity Characteristics Specificity Innate For structures shared

More information